Kahuna Workforce Solutions Secures $21 Million in Series B Funding from Resolve Growth Partners to Advance Skills Management Technology for Frontline Workers
29.11.2023 19:08:00 EET | Business Wire | Press release
Kahuna Workforce Solutions, the leading provider of operational skills and competency management software, today announced a $21 million Series B funding round led by Resolve Growth Partners. This investment marks a significant milestone in Kahuna’s growth journey and solidifies the criticality of skills management for industries with technical frontline workforces.
As organizations navigate an ever-evolving and complex landscape, understanding, validating, and aligning workforce skills to strategic business objectives is central to operating at the highest level. Kahuna is at the forefront of skills management technology, equipping organizations with actionable skill insights for effective assessment, training and development, and staffing and deployment initiatives, ultimately enabling resilient operations, improved productivity, and a more competitive workforce.
Kahuna’s customer base of leading Fortune 500 energy, manufacturing, and field service organizations, and world-renowned healthcare systems, is a testament to the platform’s scalability and robustness in meeting the rigorous demands of complex operational needs. The flagship skills management platform digitizes granular skills data, removing the burden that often comes with tracking skills manually in Excel spreadsheets or a traditional HRIS. Organizations can dynamically track skills, identify and analyze skills gaps, and provide targeted development opportunities whether at the bedside, in the field, or on the plant floor.
Kahuna plans to use the growth funding strategically to accelerate and enhance product development and innovation; expand its team by adding key roles across sales and marketing, product development, customer success, and engineering; and increase operational capabilities to continue supporting global customers as they adopt skills-based strategies to achieve operational excellence.
“We are thrilled to work with Resolve as Kahuna begins the next growth phase. Their expertise in enterprise software, and commitment to innovation and continuous improvement fully aligns with our mission, vision, and goals for Kahuna,” said Jai Shah, CEO of Kahuna Workforce Solutions. “This funding fuels our ability to provide mission-critical skills management solutions and support as we revolutionize how organizations manage and optimize workforce skills and capabilities.”
“Kahuna stands out as a category leader, as demonstrated by the quality of logos in their portfolio. They offer best-in-class skills management software and create true partnerships with customers to achieve transformative business value and operational outcomes,” said Jit Sinha, Co-Founder and Partner at Resolve Growth Partners. “Kahuna’s extensive understanding of market needs positions them uniquely in this space. Our investment is a testament to the confidence we have in Kahuna to continue leading and offering unparalleled solutions to meet the evolving needs of customers globally.”
With Resolve’s partnership, this round of funding positions Kahuna to expand its impact, empowering organizations to build resilient, future-ready workforces with operational skilling tools and initiatives for frontline workers.
About Resolve Growth Partners
Resolve Growth Partners is a growth equity firm focused on investing in B2B software companies and enabling passionate, committed entrepreneurs to accelerate growth. Resolve provides expertise and repeatable best practices across talent, go-to-market, and operations. For more information on Resolve, visit http://www.resolvegrowth.com.
About Kahuna Workforce Solutions
Kahuna Workforce Solutions is the only skills management software built for operations, learning, and human resources. Kahuna equips enterprise organizations with validated skills data to understand workforce capability, align talent supply and demand, and increase the return on training investment. Across a wide array of industries including healthcare, energy, manufacturing, and aerospace, Kahuna helps organizations build a more skilled, competitive workforce. For more information, visit https://kahunaworkforce.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231129383752/en/
Contact information
Torrye Metoyer
Director of Marketing
torrye.metoyer@kahunaworkforce.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 13:01:00 EEST | Press release
TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA AI models and tools to further enhance capabilities across advanced reasoning, autonomous analysis and video intelligence. The integration allows TACTICAAI to draw on NVIDIA’s AI ecosystem while maintaini
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 13:01:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 11:00:00 EEST | Press release
Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and vulnerability management, infrastructure protection and specialist consultancy. The Company serves more than 250
EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 10:00:00 EEST | Press release
EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 10:00:00 EEST | Press release
Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
